Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
A nurse prepares a Sinovac's COVID-19 vaccine in China. Photo: VCG/VCG via Getty Images
China's health regulator has approved the two-shot coronavirus vaccine developed by domestic drugmaker Sinovac Biotech Ltd. for general public use.
Why it matters: Sinovac's CoronaVac is the second vaccine to receive authorization in the country. State-owned pharmaceutical company Sinopharm produced the first vaccine to receive approval in China last December.
The big picture: The conditional approval means that the vaccine can be administered to the public, but more research is needed to ensure the benefits outweigh any adverse effects, per AP.
- The vaccine received emergency approval last summer for health workers to be inoculated.
- Health officials hope to inoculate 50 million people before Chinese New Year on Feb. 11, Bloomberg reports.
- The Sinovac vaccine has been sold to at least 10 other countries and is already being distributed in at least five nations, AP says.
Worth noting: Sinovac has faced criticism "due to a lack of transparency around clinical trial data," The Wall Street Journal writes.
- Several phase 3 trials in Brazil, Turkey and Indonesia have shown efficacy rates between 50.38% to 91.25%, per Bloomberg.